Taiwan synthesizes anti-viral drug favilavir for COVID-19 patients

Taiwan's non-profit Development Center for Biotechnology (DCB) announced Monday that it has synthesized favilavir, an experimental medication being used in other countries as an investigational therapy to combat the COVID-19 coronavirus.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)